June 30, 2016

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

Non-dilutive financing enhances financial strength Non-dilutive financing enhances financial strength June 30, 2016 04:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75… Read More
learn more
June 30, 2016

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

Non-dilutive financing enhances financial strength Non-dilutive financing enhances financial strength June 30, 2016 04:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75… Read More
learn more
June 30, 2016

Novocure to Report Second Quarter 2016 Financial Results

June 30, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 a.m. EDT before the open of… Read More
learn more
June 30, 2016

Novocure to Report Second Quarter 2016 Financial Results

June 30, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 a.m. EDT before the open of… Read More
learn more
June 8, 2016

Novocure to Present at JMP Securities 2016 Life Sciences Conference

June 08, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure’s Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences Conference in New York. Mr. Ambrogi will present… Read More
learn more
June 8, 2016

Novocure to Present at JMP Securities 2016 Life Sciences Conference

June 08, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure’s Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences Conference in New York. Mr. Ambrogi will present… Read More
learn more
June 8, 2016

Novocure to Present at JMP Securities 2016 Life Sciences Conference

June 08, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure’s Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences Conference in New York. Mr. Ambrogi will present… Read More
learn more
May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more
May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more
May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more